www.hivandhepatitis.com

Back HCV Treatment

Janssen Discontinues Hepatitis C Drug Development Program

Details
Category: HCV Treatment
Published on Thursday, 21 September 2017 00:00
Written by Janssen
  • Print

Janssen Sciences announced last week that it will stop further development of its experimental hepatitis regimen containing AL-335, odalasvir, and simeprevir, as the market is saturated with effective therapies. It will instead focus on hepatitis B, which is seldom cured with existing antiviral medications.

alt

Read more:

Subcategories

Copyright © 2023 www.hivandhepatitis.com. All Rights Reserved. Designed by JoomlArt.com. Joomla! is Free Software released under the GNU General Public License.

Bread and Roses Web DesignWeb Design and Development by Bread and Roses Web Design